However, despite measuring cytotoxicity/proliferation, viability as well as invasion of thyroid cancer cells, using both pharmacologic and genetic NF-κB pathway inhibition and employing two algorithms for the computation of the combination effect, the evidence for synergistic activity was limited. The gene discussed is NFKB1; the disease is thyroid gland carcinoma.